Feedback plc Deepens NHS Integration as Losses Widen and National Bleepa Bid Advances

The latest announcement is out from Feedback ( (GB:FDBK) ).

Feedback plc reported stable first-half revenue of £0.41m to 30 November 2025, with its Bleepa platform contributing 89% of sales, while adjusted EBITDA losses widened to £1.61m due to increased hiring and cloud technology investment. Cash fell to £3.82m as the company invested in product and rollout capability, but management said it retains funding runway into mid-2027 and is positioning for scale-up in 2026/27.

Operationally, Feedback completed key integrations of Bleepa with core NHS systems such as the electronic referral service, and expanded its use at Queen Victoria Hospital, including running a Non Site Specific Symptoms cancer pathway. The platform was also selected to support national simulations of the new Neighbourhood Health Service, demonstrating potential reductions in outpatient appointments and unplanned admissions and reinforcing its role in new care models.

A national business case for Bleepa has been submitted under the NHS Spending Review, which, if successful, could lead to material national or regional adoption, though the outcome is still pending. The company has paused its Indian operations to concentrate on the UK, is in late-stage discussions on strategic partnerships with consulting, cloud, and technology firms, and continues to renew all existing client contracts while engaging with NHS stakeholders at national, regional, and trust levels.

The most recent analyst rating on (GB:FDBK) stock is a Hold with a £10.50 price target. To see the full list of analyst forecasts on Feedback stock, see the GB:FDBK Stock Forecast page.

Spark’s Take on GB:FDBK Stock

According to Spark, TipRanks’ AI Analyst, GB:FDBK is a Neutral.

The score is held down primarily by deteriorating financial performance (sharp revenue decline, very large/worsening losses, and ongoing cash burn), partially offset by a debt-free balance sheet. Technicals add modest support due to an upward trend, but extremely overbought signals raise near-term risk. Valuation provides limited support given negative earnings and no dividend yield data.

To see Spark’s full report on GB:FDBK stock, click here.

More about Feedback

Feedback plc is a UK-based clinical infrastructure specialist that provides digital connectivity and asynchronous collaboration tools for healthcare. Its flagship product, Bleepa, is an award-winning SaaS collaboration platform that integrates with NHS systems to streamline patient pathways, support the shift to community-based care, and improve productivity for public and private healthcare providers, including the NHS.

The company focuses on system integration to enable secure information sharing, flexible team working, and more efficient care delivery. With a highly scalable software model and recurring contracts, Feedback is targeting domestic and international growth, but is currently prioritising the substantial UK market opportunity and national-scale deployments within the NHS.

Average Trading Volume: 90,483

Technical Sentiment Signal: Sell

Current Market Cap: £4.71M

See more insights into FDBK stock on TipRanks’ Stock Analysis page.